Effects of Atomoxetine in Mild Cognitive Impairment
Completed · Phase 2 · Has a placebo group
Conditions studied: Mild Cognitive Impairment
In brief
The purpose of this study is to evaluate the safety of atomoxetine and its effect primarily on the biologic markers (substances that may indicate the presence of a disease) in the cerebrospinal fluid (CSF) of participants diagnosed with Mild Cognitive Impairment (MCI). Additionally, information will be gathered to identify the dose of atomoxetine that is most beneficial, and how taking this medication affects thinking and behavior, as well as imaging and blood biomarkers.The study will also explore rates of change in biomarkers of neurodegeneration (Aß, tau, brain atrophy rates). The results of this research will help determine if atomoxetine alters signs of inflammation and other biomarkers associated with Alzheimer's disease.
Key facts
- Study ID
- NCT01522404
- Run by
- Emory University
- People needed
- 39
- Starts
- 2012-03-01
- Expected to finish
- 2018-06-30
- Last updated by the study team
- 2019-07-23
Who can join
Age: 50 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Emory University School of Medicine — Atlanta, Georgia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.